Table 3.

Incidence of AE (grade 3/4) related to costs collected from the FIRE-3.

Item(%)	Cmab-Grade3	Cmab-Grade4	Bmab-Grade3	Bmab-Grade4
Haematotoxicity	21%	4%	16%	14%
Skin reaction	24%	2%	2%	0%
Acneiformexanthema/rash	17%	0%	0%	0%
Liver toxicity	6%	1%	6%	<1%
Diarrhea	10%	1%	11%	2%
Nausea	3%	0%	5%	0%
Pain	5%	0%	7%	0%
Hypokalaemia	7%	<1%	2%	<1%
Vomiting	2%	0%	3%	0%
Hypertonia	6%	<1%	7%	0%
Thrombosis	6%	0%	6%	<1%
Thromboembolic event	3%	2%	2%	3%

Bmab, Bevacizumab;Cmab, Cetuximab; AE, adverse event.